ArticleAmerican journal of clinical oncology2019
Small Cell Carcinoma of the Esophagus: A Nationwide Analysis of Treatment and Outcome at Patient Level in Locoregional Disease.
Article in American journal of clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 34 citations in OpenAlex.
- Extensive-stage small cell esophageal carcinoma: a retrospective analysis of treatment modalities.BMC cancer · 2026Article
- Sequential Esophageal Squamous Cell Carcinoma and Small Cell Carcinoma Following Prior Nissen Fundoplication.Cureus · 2026Article
- Treatment strategies for small cell carcinoma of the esophagus: comparative analysis of multimodal regimens in two independent real-world cohorts.The oncologist · 2026Article
- Pattern of Lymph Node Metastases and Recurrence in Thoracic Small Cell Esophageal Carcinoma: A Single-Institution Experience.Annals of surgical oncology · 2026Article
- Development and external validation of two nomograms for predicting brain metastases and brain metastasis-free survival in primary small cell carcinoma of the esophagus: a retrospective multicenter analysis.Therapeutic advances in medical oncology · 2026Article
- Esophageal Small Cell Carcinoma: From Bench Discoveries to Bedside Therapeutics.International journal of biological sciences · 2026Review
- Clinicopathological Spectrum and Survival in Esophageal Neuroendocrine Carcinoma and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms: A 74-Patient Cohort.Cancer management and research · 2026Article
- Survival analysis of small cell carcinoma of the esophagus: a 15-year retrospective study from a high-incidence region.Journal of gastrointestinal oncology · 2025Article
- Epidemiology, prognostic factors, and survival analysis in small cell esophageal carcinoma: A population-based study with external validation.Biomolecules & biomedicine · 2025Article
- Multimodality Therapy and Survival Outcomes in Resectable Primary Small Cell Carcinoma of the Esophagus: A Multicenter Retrospective Study.Annals of surgical oncology · 2025Article
- Development and validation of a prognostic model for overall survival in small cell carcinoma of the esophagus.Frontiers in oncology · 2025Article
- TOP2A as a prognostic biomarker in small cell carcinoma of the esophagus: an integrated bioinformatics and immunohistochemical study.Frontiers in molecular biosciences · 2025Article
- Treatment strategies for limited-stage small cell carcinoma of the esophagus: evidence from a Chinese multicenter cohort study and the American SEER database.Journal of thoracic disease · 2024Article
- Prognostic factors and treatment strategies of limited-stage primary esophageal small-cell carcinoma-a SEER database analysis.Translational cancer research · 2024Article
- Epigastric Pain and Dysphagia in a 36-Year-Old Man Due to Primary Esophageal Small Cell Carcinoma.The American journal of case reports · 2024Article
- Case report: A case of esophageal small cell carcinoma misdiagnosed as leiomyoma.Frontiers in medicine · 2024Article
- Article
- Late-stage esophageal neuroendocrine carcinoma in a patient treated with tislelizumab combined with anlotinib: a case report.The Journal of international medical research · 2023Article
- Clinical predictors of special type of esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2023Review
- Primary Esophageal Small Cell Neuroendocrine Carcinoma in a Child: A Case Report with Review on Demography, Presentation, Treatment, and Survival.Advanced biomedical research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 15 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeSmall cell carcinoma of the esophagus (SCEC) is a rare subtype of esophageal cancer for which optimal treatment is unknown. We analyzed the impact of treatment factors on outcome in patients with nonmetastasized SCEC.
methodsPatients with a histologically confirmed SCEC without distant metastases were analyzed in a nationwide multicenter retrospective cohort. All patients received radiotherapy as part of curative treatment between January 2000 and December 2014. Details on treatment and outcome were retrieved from individual charts. Cox regression analysis was used to determine prognostic factors for survival.
resultsFifty-eight patients were analyzed. Median survival was 16 months (95% confidence interval, 11-21 mo). Infield recurrences occurred in 25%, distant metastases in 45%, and brain metastases in 12%. In total, 63% of patients developed a recurrence. Most recurrences (67%) occurred within 1 year. In univariable analyses an increased number of chemotherapy cycles (>3) and lower radiotherapy doses (<45 Gy) were associated with improved survival. T-stage, N-stage, treatment period, type of chemotherapy, prophylactic cranial irradiation, and age were not associated with survival. In multivariable analyses, only the number of chemotherapy cycles was associated with better survival (hazard ratio, 0.78; P=0.006).
conclusionsSCEC recurs frequently at distant sites after definitive chemoradiotherapy and usually within 1 year after curative treatment. With a dose of 45 to 50 Gy, infield recurrence rate was low. We found a relationship between number of received chemotherapy cycles and survival with best results obtained after at least 4 cycles of chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.